PrescriptionDrugs.org

What to Expect When Starting Metformin

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Metformin is the most widely prescribed first-line medication for type 2 diabetes worldwide, with over 80 million prescriptions dispensed annually in the United States alone [1][2]. It works primarily by reducing hepatic glucose production and improving peripheral insulin sensitivity through activation of AMP-activated protein kinase (AMPK) [2]. The American Diabetes Association recommends metformin as initial pharmacotherapy for most adults with type 2 diabetes, supported by decades of clinical evidence demonstrating its efficacy, cardiovascular benefits, and favorable safety profile [5].

While metformin is generally well-tolerated long-term, gastrointestinal side effects during the initiation period are its most well-known challenge. Approximately 20-30% of patients experience GI symptoms such as diarrhea, nausea, bloating, or abdominal discomfort when starting the medication [2][4]. These symptoms are dose-related and typically transient — most patients find they improve substantially within the first 2-4 weeks as the body adapts [4]. The extended-release (ER) formulation, which releases the drug more gradually, reduces GI side effects by approximately 50% compared to the immediate-release version [6].

Understanding what to expect during the titration period can help you stick with this effective medication through the adjustment phase. Metformin's benefits extend well beyond blood sugar control: a landmark meta-analysis found that metformin use was associated with reduced all-cause mortality and cardiovascular events in patients with type 2 diabetes [3]. Always follow your healthcare provider's dosing instructions.

Week-by-week timeline

Week 1-2GI side effects affect about 20-30% of patients initially but are dose-related and typically transient [2][4]. Taking metformin with food reduces symptoms significantly. If immediate-release causes persistent GI issues, the extended-release formulation reduces GI adverse events by roughly 50% [6].

Starting Low

Most providers start at 500 mg once or twice daily, taken with meals [1]. This conservative initiation dose allows your gastrointestinal system to adjust to metformin's effects on the gut. GI side effects are most common during this period, affecting approximately 20-30% of patients [2][4]. The predominant mechanism is local irritation of the intestinal lining and changes in bile salt metabolism, which is why taking the medication with food is critical [6]. In clinical practice, starting at 500 mg with the evening meal and increasing gradually produces the best tolerability outcomes.

  • Stomach upset or mild nausea (most common in the first 1-2 weeks)
  • Diarrhea or loose stools (reported by approximately 15-20% of patients initially)
  • Bloating, flatulence, and abdominal discomfort
  • Metallic taste in the mouth (~3% of patients)
  • Decreased appetite (mild, sometimes beneficial)
Week 3-4If diarrhea is persistent or disruptive at this dose, ask your provider about switching to the extended-release (ER) formulation. ER metformin produces equivalent HbA1c reduction with significantly fewer GI symptoms [6]. Do not increase the dose faster than your provider recommends.

Dose Increase

Your provider may increase the dose to 1000 mg daily (500 mg twice daily with meals) [1]. GI symptoms often return briefly at each dose increase but typically less severely and for a shorter duration than at initiation. Gradual titration — increasing by 500 mg every 1-2 weeks — is the standard approach recommended in the prescribing information to minimize GI intolerance [1][4]. Fasting blood glucose levels typically begin declining within the first 1-2 weeks, though full glycemic effect requires higher doses [2].

  • Brief return of mild GI symptoms at the new dose level
  • Gradual improvement in fasting blood sugar levels
  • Metallic taste usually fading
  • Appetite may decrease slightly — metformin is weight-neutral to mildly weight-negative, unlike many diabetes medications
  • Diarrhea and bloating improving from the initial week
Month 2-3If GI symptoms persist beyond 3-4 weeks at a stable dose, discuss alternatives with your provider. Approximately 5% of patients cannot tolerate metformin at any dose, and alternative first-line agents are available [4].

Reaching Target Dose

Your dose may increase to 1500-2000 mg daily, the typical therapeutic range [1]. The maximum recommended dose is 2550 mg/day for immediate-release and 2000 mg/day for extended-release. Blood sugar improvements become more consistent — metformin at therapeutic doses typically reduces HbA1c by 1.0-1.5% from baseline [2][5]. Most patients find GI symptoms have significantly improved or resolved by this point as gut adaptation is complete [4]. Unlike sulfonylureas or insulin, metformin does not cause hypoglycemia when used as monotherapy [1].

  • Fasting blood sugar levels trending downward consistently
  • GI side effects diminished or resolved for most patients
  • Possible modest weight stability or mild weight loss (average 1-3 kg vs. other diabetes drugs that cause weight gain)
  • Improved energy levels as blood sugar stabilizes
  • Most patients well-adjusted to the medication routine
Month 3-6Your provider will monitor vitamin B12 levels periodically, as long-term metformin use can reduce B12 absorption in approximately 5-10% of patients [7]. Annual B12 monitoring is recommended, especially for patients on higher doses or those with symptoms of neuropathy.

Full Therapeutic Effect

Metformin reaches its full blood-sugar-lowering effect within 2-3 months at target dose [2]. Your provider will check your HbA1c (a marker of average blood sugar over 3 months) to assess the response. The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced diabetes-related death by 42% and all-cause mortality by 36% in overweight patients with type 2 diabetes — benefits that went beyond glucose control [8]. A more recent meta-analysis confirmed these cardiovascular benefits [3]. Most side effects have resolved by this stage.

  • HbA1c improvement typically 1.0-1.5% from baseline at therapeutic doses
  • Stable digestion for most patients — GI adaptation is complete
  • Weight neutral or modest weight loss (unlike insulin or sulfonylureas)
  • Improved overall metabolic markers including modest lipid improvements
  • Continued cardiovascular risk reduction accruing over time

When to call your doctor

Contact your healthcare provider if you experience:

  • Signs of lactic acidosis — a rare (incidence ~0.03-0.06 per 1,000 patient-years) but serious complication: unusual muscle pain or cramping, difficulty breathing, unusual sleepiness, stomach pain with nausea/vomiting, feeling unusually cold, or dizziness [1][2]
  • Severe or persistent diarrhea causing dehydration — dark urine, reduced urination, dizziness, or rapid heartbeat [1]
  • Signs of hypoglycemia if taking metformin with insulin or sulfonylureas: shakiness, sweating, confusion, rapid heartbeat (metformin alone does not cause hypoglycemia) [1]
  • Allergic reaction symptoms: skin rash, hives, swelling of the face or throat, difficulty breathing [1]
  • Yellowing of skin or eyes (jaundice), dark urine, or severe fatigue, which may indicate hepatic dysfunction [1]
  • Symptoms of vitamin B12 deficiency during long-term use: numbness or tingling in hands/feet, balance problems, fatigue, or cognitive changes [7]
  • You are scheduled for surgery or a procedure using IV contrast dye — inform the medical team that you take metformin, as it must be temporarily discontinued [1]
  • Acute illness causing significant dehydration, vomiting, or reduced kidney function — metformin may need to be temporarily held [1]

Tips for getting started

Always take metformin with food — this is the single most effective strategy for reducing GI side effects, as food slows the release of metformin in the gut and reduces peak intestinal concentrations [1][2]. The FDA prescribing information specifically recommends administration with meals. Patients who take metformin on an empty stomach are significantly more likely to experience nausea and diarrhea.

If GI side effects are problematic, ask your provider about the extended-release (ER) formulation. Clinical studies show that the ER version causes fewer GI symptoms while delivering equivalent glycemic control [6]. The ER formulation is taken once daily, usually with the evening meal, which also simplifies the dosing schedule. If your provider starts you on immediate-release (IR) metformin and GI issues persist beyond 2-3 weeks, the switch to ER is a well-established next step [4].

Stay well hydrated, especially if experiencing diarrhea — aim for at least 64 ounces of water daily. Avoid excessive alcohol consumption, as alcohol increases the risk of lactic acidosis (metformin's most serious, though rare, adverse effect) and can independently cause hypoglycemia [1]. The FDA label recommends limiting alcohol intake.

If you experience a persistent metallic taste — reported by approximately 3% of patients — sugar-free mints or citrus-flavored lozenges can help [2]. Be aware that metformin can reduce vitamin B12 absorption over time: a clinical trial found that 5.8% of metformin users developed B12 deficiency over 4 years, compared to 2.4% with placebo [7]. Ask your provider about periodic B12 monitoring, especially if you develop symptoms like numbness, tingling, or unusual fatigue.

Frequently asked questions

More about Metformin

Metformin drug guideSide effects, dosage, interactions, and moreSemaglutide (Ozempic) vs MetforminCompare these medicationsMetformin vs SemaglutideCompare these medicationsMetformin vs PioglitazoneCompare these medicationsSemaglutide & MetforminInteraction detailsLisinopril & MetforminInteraction detailsAtorvastatin & MetforminInteraction details

References

  1. [Regulatory] Metformin Hydrochloride FDA Prescribing Information. Revised 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020357s043lbl.pdf Accessed 2025-01-15.
  2. [Regulatory] Metformin. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK518983/ Accessed 2025-01-15.
  3. [Clinical] Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause mortality and cardiovascular events in type 2 diabetes. Diabetes Obes Metab. 2023;25(4):985-993. https://pubmed.ncbi.nlm.nih.gov/36176044/ Accessed 2025-01-15.
  4. [Clinical] McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426-435. https://pubmed.ncbi.nlm.nih.gov/28427509/ Accessed 2025-01-15.
  5. [Regulatory] American Diabetes Association. Standards of Care in Diabetes — 2023. Diabetes Care. 2023;46(Suppl 1):S1-S291. https://pubmed.ncbi.nlm.nih.gov/36805446/ Accessed 2025-01-15.
  6. [Clinical] Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin compared to immediate-release metformin. Curr Med Res Opin. 2004;20(4):565-572. https://pubmed.ncbi.nlm.nih.gov/15317625/ Accessed 2025-01-15.
  7. [Clinical] de Jager J, Kooy A, Lehert P, et al. Long-term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency. BMJ. 2010;340:c2181. https://pubmed.ncbi.nlm.nih.gov/20028952/ Accessed 2025-01-15.
  8. [Clinical] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. https://pubmed.ncbi.nlm.nih.gov/9742976/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: